{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:13:01Z","timestamp":1784776381793,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2018SZ0219"],"award-info":[{"award-number":["2018SZ0219"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZY2016104"],"award-info":[{"award-number":["ZY2016104"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>The objective of this study was to investigate the platelet-to-lymphocyte ratio (PLR) in patients who underwent intravesical treatment for non-muscle invasive bladder cancer (NMIBC). A total of 197 patients who underwent intravesical Bacillus Calmette-Guerin treatment after transurethral resection of bladder (TURB) were included. We divided the patients into different groups according to the treatment stage before and during induction treatment as Group 1 and Group 2, and set the change value of PLR as the Group 3. The cutoff values of PLR were determined through receiver operation characteristics curves analysis. we found a significant difference in recurrence-free survival (RFS) and progression-free survival (PFS) between patients with high serum PLR and those with low serum PLR in Group 1, as well as Group 2. Cox multivariate analysis revealed that tumor number \u22653, high grade, and history of carcinoma in situ (CIS) were significant factors predicting RFS and PFS. The PLR values before and during induction therapy could be used as predictors for the progression and recurrence of NMIBC patients receiving BCG immunotherapy. the PLR values after induction therapy have a stronger predictive power.<\/jats:p>","DOI":"10.3389\/fsurg.2022.907485","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T05:50:52Z","timestamp":1653285052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic Value of Platelet-to-Lymphocyte Ratio in Non-Muscle Invasive Bladder Cancer Patients: Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor"],"prefix":"10.3389","volume":"9","author":[{"given":"Ruicheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengxiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non\u2013muscle-invasive bladder cancer patients initially treated with bacillus calmette-gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer: INTRAVESICAL BCG PLUS TUR VS TUR ALONE IN TA AND T1 BLADDER CANCER","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","article-title":"The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma","volume":"175","author":"Kamat","year":"2006","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus calmette-gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eururo.2015.01.032","article-title":"Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature","volume":"68","author":"Kluth","year":"2015","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/bjc.2012.211","article-title":"The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer","volume":"106","author":"Richards","year":"2012","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/OTT.S94458","article-title":"Prognostic value of peripheral blood lymphocyte-to-monocyte ratio in patients with solid tumors: a meta-analysis","volume":"37","author":"Li","year":"2015","journal-title":"OncoTargets Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","article-title":"Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis","volume":"483","author":"Li","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.urolonc.2018.05.014","article-title":"Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non\u2013muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis","volume":"36","author":"Vartolomei","year":"2018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7375169","DOI":"10.1155\/2018\/7375169","article-title":"Prognostic significance of platelet-to-lymphocyte ratio in cholangiocarcinoma: a meta-analysis","volume":"2018","author":"Hu","year":"2018","journal-title":"BioMed Res Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/DCR.0000000000002291","article-title":"Prognostic significance of lymphocyte-to-monocyte and platelet-to-lymphocyte ratio in rectal cancer: a systematic review, meta-analysis, and meta-regression","volume":"65","author":"Hamid","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"B24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3389\/fonc.2019.00757","article-title":"Prognostic role of platelet-to-lymphocyte ratio in patients with bladder cancer: a meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2174\/138161209788453167","article-title":"Inflammation, microenvironment, and the immune system in cancer progression","volume":"15","author":"Keibel","year":"2009","journal-title":"Curr Pharm Des"},{"key":"B28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Stone","year":"2012","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells","volume":"105","author":"Palumbo","year":"2005","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-016-0145-x","article-title":"B cell regulation of the anti-tumor response and role in carcinogenesis","volume":"4","author":"Schwartz","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","article-title":"Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis","volume":"23","author":"Guan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/jop.12832","article-title":"Prognostic role of platelet-to-lymphocyte ratio in oral cancer: A meta-analysis","volume":"50","author":"Zhang","year":"2021","journal-title":"J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/cancers14020438","article-title":"The value of platelet-to-lymphocyte ratio as a prognostic marker in cholangiocarcinoma: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3389\/fonc.2019.00757","article-title":"Prognostic role of platelet-to-lymphocyte ratio in patients with bladder cancer: a meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille calmette-gu\u00e9rin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bju.13146","article-title":"Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy","volume":"117","author":"Moschini","year":"2016","journal-title":"BJU Int"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.907485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T15:08:23Z","timestamp":1660230503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.907485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":38,"alternative-id":["10.3389\/fsurg.2022.907485"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.907485","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"article-number":"907485"}}